Back to RHUMBLINE ADVISERS RHUMBLINE ADVISERS

MREOMREO
Showing 8 of 13 quarters

Position history for RHUMBLINE ADVISERSRHUMBLINE ADVISERS's holdings in MEREO BIOPHARMA GROUP PLC

Yes. RhumbLine Advisers holds 26,784 shares of MREO (Mereo Biopharma Group), worth $8,511, as of its Q2 2026 13F filing. It increased the position by 7,212 shares (+36.9%) from Q1 2026. RhumbLine Advisers has held MREO since Q2 2023, across 13 quarterly 13F filings.

Current Value

$8,511

Current Shares

26,784

Total Value Change

-$21,372

Total Shares Change

+19,511

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
26,784
+36.9%
$8,5110.0%$0.32
15
2026-Q1
Increased
19,572
+2.2%
$6,4520.0%$0.41
11
2025-Q4
Increased
19,146
+109.9%
$7,9770.0%$0.37
18
2025-Q3
Decreased
9,122
-7.7%
$18,7880.0%$1.96
0
2025-Q2
Increased
9,878
+49.9%
$26,7660.0%$2.66
18
2025-Q1
Decreased
6,588
-9.0%
$14,8180.0%$2.30
0
2024-Q4
Decreased
7,237
-0.5%
$25,3270.0%$3.52
0
2024-Q3
Increased
7,273
+4.5%
$29,8830.0%$4.14
14

Other major holders of MREO: Janus Henderson Group Ltd., ADAGE CAPITAL PARTNERS GP, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used